AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues
By Adria Calatayud
AstraZeneca secured European Union approval for a new breast-cancer treatment, opening a big market for the drug as U.S. regulators continue to review the company's application.
The U.K. drugmaker said Thursday that the medicine, known as camizestrant and marketed as Etcamah, was approved in the EU as part of a drug combination to treat adults with a type of advanced breast cancer. The EU nod follows earlier approvals in Japan, the United Arab Emirates and Saudi Arabia, it added.
The U.S. Food and Drug Administration recently extended its deadline to decide on the drug's authorization to review updated results from the clinical trial that was the basis for AstraZeneca's regulatory submissions, the company said.
The trial showed the Etcamah combination reduced the risk of disease progression or death versus the standard-of-care treatment, and the study will continue to assess whether patients' survival rates improve, it added.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 23, 2026 03:05 ET (07:05 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
4 Growth Stocks to Buy While They’re Still Undervalued
United States